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Abstract
Objective—This study aims to examine whether gynecologic conditions are associated with 
chronic fatigue syndrome (CFS).
Methods—This study includes a subset of 157 women from a population-based case-control 
study in Georgia, United States, conducted in 2004-2009. Gynecologic history was collected using 
a self-administered questionnaire. Crude odds ratios (ORs) with 95% CIs and ORs adjusted for 
body mass index and other covariates, where relevant, were estimated for gynecologic conditions 
between 84 CFS cases and 73 healthy controls.
Results—Cases and controls were of similar age. Women with CFS reported significantly more 
gynecologic conditions and surgical operations than controls: menopause status (61.9% vs 37.0%; 
OR, 2.37; 95% CI, 1.21-4.66), earlier mean age at menopause onset (37.6 vs 48.6 y; adjusted OR, 
1.22; 95% CI, 1.09-1.36), excessive menstrual bleeding (73.8% vs 42.5%; adjusted OR, 3.33; 95% 
CI, 1.66-6.70), bleeding between periods (48.8% vs 23.3%; adjusted OR, 3.31; 95% CI, 
1.60-6.86), endometriosis (29.8% vs 12.3%; adjusted OR, 3.67; 95% CI, 1.53-8.84), use of 
noncontraceptive hormonal preparations (57.1% vs 26.0%; adjusted OR, 2.95; 95% CI, 1.36-6.38), 
nonmenstrual pelvic pain (26.2% vs 2.7%; adjusted OR, 11.98; 95% CI, 2.57-55.81), and 
gynecologic surgical operation (65.5% vs 31.5%; adjusted OR, 3.33; 95% CI, 1.66-6.67), 
especially hysterectomy (54.8% vs 19.2%; adjusted OR, 3.23; 95% CI, 1.46-7.17). Hysterectomy 
and oophorectomy occurred at a significantly younger mean age in the CFS group than in controls 
and occurred before CFS onset in 71% of women with records of date of surgical operation and 
date of CFS onset.
Conclusions—Menstrual abnormalities, endometriosis, pelvic pain, hysterectomy, and early/
surgical menopause are all associated with CFS. Clinicians should be aware of the association 
between common gynecologic problems and CFS in women. Further work is warranted to 
determine whether these conditions contribute to the development and/or perpetuation of CFS in 
some women.
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Chronic fatigue syndrome (CFS) is a debilitating and complex illness affecting more than 1 
million US adults and accounting for sizable economic costs to the individual, healthcare 
system, and society as a whole. 1-5 CFS is characterized by profound fatigue that is 
accompanied by symptoms affecting multiple body systems, including, most 
characteristically, postexertional malaise, unrefreshing sleep, problems with memory and 
concentration, and pain. 1 The fatigue in CFS is not relieved by rest; medical or psychiatric 
conditions that could explain the fatigue and symptoms have been ruled out or fully 
managed.1 The cause of CFS remains unknown. CFS affects women two to four times more 
frequently than men, with the highest prevalence found in women in their middle to late 
40s.3-6 Although CFS is more common in women, only few studies have examined sex-
specific risk factors for CFS. A case-control study with a population-based sample of 
women with CFS (n = 22) identified hysterectomy as a risk factor for CFS.7 Another case-
control study of women with CFS (n = 150) from a tertiary referral center found 
endometriosis, ovarian cysts, polycystic ovaries, uterine fibroids, menstrual abnormalities, 
and galactorrhea to be risk factors for CFS.8 Furthermore, Harlow et al8 and Studd and 
Panay9 hypothesized that a deficiency or imbalance in endogenous sex hormones may be a 
risk factor for CFS in some women. We recently reported that endometriosis, irregular 
periods, a history of gynecologic surgical operation, and pelvic pain unrelated to 
menstruation were all significantly associated with CFS in a population-based sample from 
Wichita, KS.10 Using the conceptual framework that irregular periods, bleeding between 
periods, menopause, and oophorectomy could be indicators of gonadal hormone deficiency, 
we examined the association between gynecologic conditions and CFS in this study to 
replicate previous findings and to explore additional risk indicators.
METHODS
Data were obtained from the follow-up phase (T1) of a two-wave population-based 
longitudinal study of CFS and fatiguing illness in Georgia, United States, conducted 
between 2004 and 2009.6 Sampling methodology and study participants have been described 
in detail elsewhere6 and are briefly summarized later and in the flow chart (Fig. 1). The 
study was approved by the Institutional Review Boards of the Centers for Disease Control 
and Prevention and Abt Associates. All participants gave written informed consent.
Recruitment of participants
The baseline study (T0) took place in 2004-2005 and has been described in detail 
previously.6 In brief, the baseline study included a random-digit-dialing household screening 
interview to identify household residents aged 18 to 59 years from 14 Georgia counties, 
including metropolitan, urban, and rural areas. This enumerated 19,807 individuals screened 
(residing in 10,873 households reached of 11,247 working eligible residential numbers; ie, 
96% participation rate).6 The screening interview was followed by individual computer-
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assisted telephone interview (CATI) to identify: (i) participants who met the interview 
criteria for CFS-like illness (CFS-like group); (ii) participants who were well (control 
group); or (iii) participants who had been unwell for a long time (an intermediate group with 
some case-defining CFS symptoms [eg, cognition problems, unrefreshing sleep, or pain] 
with or without fatigue). Controls were identified to match CFS-like cases on age (within 3 
y), sex, race/ethnicity, and geographic area. All CFS-like cases, their matched controls, and a 
similar number of participants randomly selected from the intermediate group were invited 
for baseline (T0) clinical evaluation; 783 completed it (Fig. 1). The clinical evaluation 
(performed by physicians, trained psychologists, and nurses) included medical history, 
physical examination, laboratory tests, psychiatric evaluation, and a battery of instruments to 
measure symptoms, functionality, and impairment. The data collected during the clinical 
evaluation were used by a panel of physicians and other researchers to identify comorbid 
and/or exclusionary medical and psychiatric conditions and to classify clinical participants 
into study groups. Participants were classified into the following groups: (i) CFS cases, 
according to the 1994 case definition based on standardized/operationalized criteria for 
fatigue, function, and symptoms; (ii) nonfatigued well controls; (iii) an intermediate group 
with insufficient number of symptoms and/or fatigue to meet full CFS case definition criteria 
(ISF); or (iv) persons with exclusionary medical or psychiatric conditions.1,6,11
The follow-up study (T1) was conducted during 2007-2009. All persons who had been to the 
clinic at baseline and did not have permanent exclusionary conditions (n = 681 eligible) 
were invited for a follow-up telephone interview and a follow-up clinical evaluation. 
Additional baseline CATI participants (with no exclusions identified in the baseline detailed 
telephone interview) were contacted for a second telephone interview. Those whose 
interview findings qualified them as new CFS-like cases or as well controls were also invited 
for a clinical evaluation (Fig. 1). A total of 919 participants were eligible and invited for T1 
clinical evaluation; 751 completed it (ie, 82% participation rate). Of these 751 participants, 
560 were women (Fig. 1, flow chart). Of these 560 women, 188 were found to have medical 
or psychiatric conditions exclusionary for CFS and were not considered for final 
classification. Final ascertainment classified participants as follows: 84 CFS cases, 73 
consistently well controls, 186 women with insufficient number of symptoms and/or fatigue 
to meet full CFS case definition criteria (ISF group), and 29 women who did not consistently 
meet criteria for nonfatigued well controls. Of the 84 women in the CFS group, 70 women 
were seen at both T0 and T1 clinics, and 14 CFS cases were only seen at T1. (Of the women 
seen at both times, 44 women fully met CFS case definition criteria both times, 12 women 
were in the ISF group at T0 and converted into CFS cases at T1, and 14 women who met 
CFS criteria at T0 were ill at T1 without sufficient symptoms or fatigue to fully meet CFS 
criteria [ISF].) The control group (n = 73) consisted of 44 women who were consistently 
classified as well controls at T0 and T1 clinical evaluations and 29 well controls who were 
clinically evaluated only at T1 (who were also consistently well at both T0 and T1 detailed 
telephone interviews). This analysis only concerned 157 women: 84 CFS cases and 73 
nonfatigued well controls (see shaded boxes at the bottom row of flow chart; Fig. 1). The 
gynecologic history questionnaire was administered only during the second wave before T1 
clinical evaluation. Although the source study was designed to have “CFS-like” cases and 
“well” controls matched on detailed telephone interviews (CATI), case-control matching 
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was broken owing to reclassification and/or diagnosis of exclusionary conditions (CFS ruled 
out) at clinical evaluation. Common reasons for exclusion of participants after the clinical 
evaluation included the following: not meeting sufficient number of criteria for CFS or for 
control and/or having hypothyroidism, anemia, or other exclusionary medical or psychiatric 
conditions.1,6
Measurements
Demographic information was collected during telephone interviews and further confirmed 
at the clinic. Height and weight were collected at the clinic as part of physical examination. 
Body mass index (BMI) was calculated as follows: BMI = weight/height2 (kg/m2).
The gynecologic history questionnaire was an adaptation of the Reproductive History 
Questionnaire/Menstruation-Menopause History developed by the National Cancer Institute 
Division of Cancer Epidemiology and Genetics.12 The gynecologic history questionnaire 
was mailed to participants before their scheduled T1 clinic visit, allowing them to complete 
the questionnaire at home and to consult their medical records (the study itself did not 
include chart review). During the clinic visit, the questionnaire was reviewed by clinic staff 
for completeness and accuracy. The gynecologic history questionnaire included the 
following: age at menarche; regularity of menstrual cycles; duration and heaviness of 
bleeding in a typical menstrual period; excessive menstrual bleeding; bleeding between 
periods; missed periods (defined as periods missed for reasons other than pregnancy, breast-
feeding, or menopause); pelvic pain unrelated to menstrual periods during the last 6 months; 
diagnosis of endometriosis; age at menopause; and use of hormones to treat irregular 
periods, menopausal symptoms, or bone loss. The questionnaire included a definition of 
menopause (“Menopause is when your periods stop for at least a year [NOT because of 
pregnancy or breast-feeding]”), which preceded questions about menopause. We assessed 
menopause status and age at menopause by responses to the questions, “Are you currently 
menopausal?” and “How old were you when your periods stopped because of menopause?” 
We also collected data on gynecologic surgical operations (yes or no) and number of 
surgical operations. Women were further asked, “Have you ever had any surgery/operation 
involving removal (either partial or total) of one or both of your ovaries, uterus (womb), or 
tubes?” They were asked, “For each surgery, please indicate the month and year of the 
surgery, what was removed during the surgery, and the reason for the surgery.” Self-
reporting of hysterectomy and bilateral oophorectomy has been shown to have a high 
positive predictive value (PPV; 97% and 100%, respectively), whereas self-reported 
unilateral oophorectomy has a PPV of 73%, with 19% of reported unilateral oophorectomies 
being actually bilateral.13 For each gynecologic surgical operation that included removal of 
the uterus, ovary, tube, or cyst, women were asked to select applicable answers from these 
possibilities: “total uterus, part of the uterus; two ovaries, one ovary; two tubes, one tube; 
other surgical operation [specify].” We collected no additional details on what was involved 
in the partial removal of the uterus. Women who reported hysterectomy (without bilateral 
oophorectomy) were classified as menopausal if they answered “yes” to the question, “Are 
you currently menopausal?” For each woman with CFS who underwent a major gynecologic 
surgical operation (ie, with removal of the entire uterus and removal of ovaries), we derived 
a new variable—the time interval between the date of that surgical operation and the date of 
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fatigue onset (derived from the Centers for Disease Control and Prevention Symptom 
Inventory). We calculated the mean interval between surgical operation and subsequent 
fatigue onset. The gynecologic questionnaire did not contain information on physical 
activity, alcohol use, or tobacco use.
Statistical analyses
Group means (SEM) were calculated for continuous variables. For categorical variables, we 
compared differences in proportions between the CFS group and the control group using χ2 
test or Fisher’s exact test, as appropriate. To estimate the association of CFS with 
gynecologic conditions, we calculated crude and adjusted odds ratios (ORs) for CFS (with 
95% CIs) using unconditional logistic regression.
We also calculated adjusted ORs that included BMI as a possible confounder because BMI 
has been shown to be significantly associated with both CFS and gynecologic conditions 
(menopause and hysterectomy).14,15 Besides the main effects, we also included an 
interaction term of each gynecologic variable and BMI in the models. In addition to BMI, 
the ORs for hysterectomy, excessive bleeding, and pelvic pain were also adjusted for 
endometriosis because it can be associated with these conditions. Statistical significance was 
set at an α of 0.05. P values were based on two-sided tests. We used SAS version 9.2 
software.
RESULTS
Overall demographic characteristics of the CFS and control groups are presented in Table 1. 
Women from the CFS and control groups did not differ significantly in age, race/ethnicity, or 
residential area (Table 1). The CFS group was less educated, had a higher proportion of 
women who were previously married, and had a lower proportion of women who were never 
married. There was no significant difference in overall household income between the 
groups; however, a higher proportion of the CFS group belonged to the lowest-income 
category (<US$30,000) compared with controls (P = 0.047; data not shown in Table 1). The 
CFS group had significantly higher BMI than controls. Of the 55 women in the CFS group 
who had data on type of illness onset, most (76.4%) reported gradual onset of their fatigue 
(data statistics not shown in Table 1). Among women with CFS, the mean (SEM) duration of 
fatigue/exhaustion was 10.1 (0.7) years.
Gynecologic variables
Mean age at menarche was the same for CFS cases and controls (12 y; Table 2). The CFS 
group had a longer mean (SEM) duration of menstrual flow (5.7 [0.2] vs 4.8 [0.2] d for 
controls). A significantly higher proportion of women in the CFS group reported excessive 
bleeding during periods (73.8% vs 42.5% in controls), bleeding between periods (48.8% vs 
23.3%), and missing periods (38.1% vs 21.9%), with OR ranging between 2.16 and 3.33 
(Table 2).
Significantly more women with CFS than controls reported having been diagnosed as having 
endometriosis (29.8% vs 12.3%; OR, 3.01; 95% CI, 1.30-6.98; Table 2). Pelvic or lower 
abdominal pain unrelated to menstrual period was significantly more common in women 
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with CFS (26.2% vs 2.7% in controls; OR, 12.60; 95% CI, 2.85-55.73), and adjusting for 
endometriosis did not significantly alter this association (Table 2).
Although women in the two groups were of similar mean age, a significantly higher 
proportion of women in the CFS group reported being menopausal (61.9% vs 37.0% in 
controls). In the subset of postmenopausal women (52 with CFS and 27 controls), those with 
CFS reported a significantly younger mean (SEM) age at menopause (38.5 [1.3] y) 
compared with controls (48.6 [0.9] y; Tables 2 and 3). Hysterectomy was experienced by 
78.8% (ie, 41 of 52) of postmenopausal women with CFS compared with 37% (ie, 10 of 27) 
of controls (P < 0.001; Table 3). Natural menopause occurred 2 years earlier in the CFS 
group compared with the control group (mean [SEM], 48.6 [1.7] vs 50.6 [0.5] y, P = 0.25). 
Hysterectomy was experienced by women with CFS at a significantly younger mean (SEM) 
age (about a decade earlier) compared with controls (35.8 [1.2] vs 45.2 [1.8] y, respectively).
Major gynecologic surgical operations
At least one gynecologic surgical operation was reported by 65.5% of women with CFS 
versus 31.5% of controls (OR, 4.12; 95% CI, 2.11-8.04; Table 2). Hysterectomy was the 
most common surgical operation (54.8% of women with CFS vs 19.2% of controls). As 
shown in Table 2, most women who reported a hysterectomy also reported removal of 
ovaries and tubes. Stratified analysis by type of hysterectomy (alone, with bilateral 
oophorectomy, or with unilateral oophorectomy) is presented in Table 2. CFS was 
significantly associated with any hysterectomy (OR, 5.10; 95% CI, 2.47-10.52), total 
hysterectomy alone (OR, 5.12; 95% CI, 1.54-17.05), hysterectomy with bilateral 
oophorectomy (OR, 3.38; 95% CI, 1.25-9.16), or hysterectomy with unilateral 
oophorectomy (OR, 7.09; 95% CI, 1.44-34.88). Early surgical menopause (at or before age 
45 y) occurred in 61.5% of postmenopausal women with CFS compared with 33.3% of 
postmenopausal controls (OR, 3.20; 95% CI, 1.21-8.49; P = 0.02; Table 3). Overall, mean 
age at time of surgical operation was younger in women with CFS than in controls, 
respectively: 35.8 (1.2) versus 45.2 (1.8) for any hysterectomy; 37.7 (2.7) vs 45.3 (2.5) for 
hysterectomy with bilateral oophorectomy; and 34.1 (1.4) vs 44.0 (3.6) for hysterectomy 
with ovarian preservation (Tables 2 and 3).
After adjustment for BMI, all gynecologic factors remained statistically significantly 
associated with CFS (Table 2). There were no statistically significant interactions between 
gynecologic variables and BMI. When total hysterectomy, age at menopause, and BMI were 
included in the model, only age at menopause remained statistically significantly associated 
with CFS (OR,1.22; 95% CI, 1.09-1.36; P < 0.001; overall model fitting, 0.96; c = 0.84).
Conditions leading to surgical operation (reasons for surgical operation)
We compared the proportions of the most common reasons for removal of the uterus and 
ovaries in the two groups in two ways. First, in a stratified analysis, we broke down the 
variable “gynecologic surgical operation” (Table 2) into several subgroups based on “reason 
for surgical operation.” CFS was strongly associated with both bleeding (OR,10.38; 95% CI, 
2.33-94.22) and uterine fibroids (OR, 3.45; 95% CI, 1.01-15.01) as reason for gynecologic 
surgical operation (data not shown). Second, we used a conservative estimate by including in 
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the denominator only women who reported gynecologic surgical operations (Table 4). 
Bleeding (as reason for surgical operation) remained significantly associated with CFS (OR, 
5.81; 95% CI,1.01-59.12). Neither of the other examined reasons—endometriosis, uterine 
fibroids, ovarian cysts, or precancerous cervical lesions—differed significantly between 
cases and controls.
Relationship between time of surgical operation and CFS onset
Of the 51 women who reported hysterectomy and/or bilateral oophorectomy and/or removal 
of both tubes, 42 had information on both date of surgical operation and date of onset of 
unusual fatigue. Of these 42 women, 30 (71.4%) had surgical operation before the onset of 
illness by a mean (SEM) of 9.1 (1.4) years (range, 0-21 y; median, 10.5 y). When we limited 
the analysis of hysterectomy to only 30 cases in which hysterectomy occurred before the 
onset of fatigue, the magnitude of the association of CFS with hysterectomy was reduced 
(OR, 1.56; 95% CI, 0.74-3.22; P = 0.24).
Use of noncontraceptive hormone therapy
Women with CFS were significantly more likely to have ever been prescribed hormonal 
preparations to treat irregular periods, menopausal symptoms, or bone loss: overall, 57.1% 
of the CFS group versus 26.0% of controls (OR, 3.79; 95% CI, 1.92-7.47), after adjustment 
for menopause status (OR, 2.95; 95% CI, 1.36-6.38). Interestingly, among the 14 women in 
the CFS group who were CFS cases at T0 and classified in the ISF group at T1, 35.7% 
reported currently using hormone therapy. Inversely, of the 12 women who were classified in 
the ISF group at T0 and became CFS cases at T1, only 16.7% (two women) were currently 
using hormones.
DISCUSSION
Our study supports previously identified associations of CFS with gynecologic conditions: 
endometriosis,8,10,16 menstrual abnormalities,8 gynecologic surgical operation (particularly 
hysterectomy),7,10,17 and pelvic pain unrelated to menstruation.10 In addition, our study 
found that CFS was associated with early hysterectomy/menopause and use of 
noncontraceptive hormonal preparations. The gynecologic conditions associated with CFS 
and the possible links between them are summarized in Figure 2. As shown in Figure 2, we 
suspect that aberrations in female sex hormones may contribute to these associations; 
however, because of cross-sectional data, our findings do not demonstrate causality.
In our study, women with CFS were four times more likely than controls to have had a 
hysterectomy. Most importantly, hysterectomy was performed at a significantly younger 
mean age in CFS cases than in controls. Our finding that only age at menopause remained 
significantly associated with CFS in the multivariate model (covariates: hysterectomy, BMI, 
and age at menopause) suggests that the risk for CFS increases with earlier reduction/
depletion of endogenous sex hormones. Indeed, premenopausal hysterectomy (even with 
ovarian preservation) precipitates ovarian failure, with documented reduction of estrogen 
and progesterone levels18 and elevation of follicle-stimulating hormone (FSH) levels.19 The 
reported early menopause (mostly postsurgical) in the CFS group (mean, 38.5 y; ie, 10 y 
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earlier than controls) bolsters our previous (not statistically significant) observation in a 
sample from a population-based case-control study in Wichita, KS.10 Before this study, a 
significant association of CFS and early menopause has not been reported. However, in 
fibromyalgia, which shares many symptoms with CFS, early menopause (<45 y) was 
reported by 38% of women in one study.20 In another study, 48% of women with 
fibromyalgia had a hysterectomy. Hysterectomy preceded fibromyalgia diagnosis in 90.7% 
of cases who had both conditions.21 Similarly, in our study, hysterectomy and oophorectomy 
preceded fatigue onset in 71% of women with available data on both. Although associations 
between hysterectomy and severity of illness have not been studied in women with CFS, in 
fibromyalgia, women who have had hysterectomy have lower physical function and greater 
severity of pain, fatigue, stiffness, and depression than those who have not had 
hysterectomy.22 In our study, CFS was also associated with menstrual irregularities and 
excessive bleeding conditions, which often may have hormonal reasons.23 Disturbed 
menstrual cycle function (including hyperprolactinemia and hyperandrogenism) in women 
with CFS has been suggested by Harlow et al8 but has barely been explored. A small study 
reported sex hormone deficiency in women with CFS and improvement in 80% with use of 
cyclic estrogen/progestogen.9 Reduced levels of ovarian sex hormones in early 
hysterectomy/early ovarian failure can have considerable nonreproductive consequences 
because sex hormones are involved in a variety of nonreproductive bodily functions (see 
later discussion). The significantly higher use of noncontraceptive female hormones in our 
CFS group may be explained by earlier menopause and/or other sex hormone abnormalities 
requiring additional hormonal support. Although the numbers were quite small to draw any 
conclusions, the proportion of current hormone use was twice as high (35.7%) in the 
subgroup that converted from CFS to ISF (ie, improved) between T0 and T1 compared with 
the subgroup that converted from ISF to CFS (current hormone use, 16.7%).
Of the gynecologic conditions examined in this study, the strongest association was found 
between CFS and pelvic pain unrelated to menstruation (with pelvic pain being least 
reported by controls [2.7%]). Possible increased pain sensitivity may underlie this 
association.24 Increased pain sensitivity may exist in several overlapping pain conditions 
(CFS, fibromyalgia, endometriosis, irritable bowel syndrome, and interstitial cystitis), with 
women often having more than one condition.17 Both estrogen and progesterone modulate 
pain in the nociceptive pathways in the spinal cord and at the central level (via interaction 
with the serotonin system).25-27 Similar to our findings, women with interstitial cystitis/
painful bladder syndrome have reported higher use of noncontraceptive female hormones,28 
suggesting coexisting hormonal problems. Both estrogen and progesterone have numerous 
nonreproductive functions29-39: they are neuroprotective29-31; they influence sleep,32 
cognition,33,34 and immune responses/inflammation35-37; they support muscle, joint, and 
bone health38; and they modulate pain sensitivity39—all of which are present in the 
symptom domains of CFS. A detailed discussion of the various nongynecologic effects of 
female hormones is beyond the purpose of this study. Notably, however, both physical and 
mental stressors, which have been implicated in the pathogenesis of CFS, can compromise 
sex hormone production via the hypothalamopituitary axis.
Although our sample size (N = 157) was not large, the study’s strengths include its 
population-based design (with sample identified from random-digit-dialing telephone 
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screening interviews covering 19,807 residents in Georgia),6 detailed gynecologic history, 
and extensive clinical workup to correctly define cases and controls and to rule out 
conditions other than CFS that could explain the symptoms. Limitations of our study include 
self-reported (not chart-abstracted) conditions, potential selection bias (from 
nonparticipation), inability to adjust for tobacco and alcohol use, and possible recall bias. 
However, completing the questionnaire at home allowed participants to consult their medical 
records, which potentially reduced recall bias. Furthermore, validation studies of self-
reported hysterectomy and bilateral oophorectomy have shown high PPVs (97% and 100%, 
respectively) with moderate specificity (ie, under-reporting of bilateral oophorectomy).13 
Our study sample was population-based and was identified using the 1994 case definition; 
therefore, it may not be representative of women with CFS seen in tertiary clinical practice. 
The findings may also not be generalizable to all women with CFS because most cases in 
our study had gradual CFS onset. In our study, some women who have had hysterectomy 
(alone or with unilateral oophorectomy) were possibly misclassified as menopausal if their 
hysterectomy occurred before biological menopause. Therefore, in women who have had 
hysterectomy with ovarian preservation, age at menopause was probably an underestimate. 
However, even if we disregard age at menopause for the abovementioned reason and 
examine only mean age at hysterectomy as a risk factor, the CFS group had a significantly 
younger age at hysterectomy (mean, 8-10 y earlier than the control group; Table 2), and 
early hysterectomy (at <45 y) was significantly more common in the CFS group. Although 
ovarian function will probably continue after removal of the uterus with ovarian preservation 
(ie, hysterectomy alone or with unilateral oophorectomy), prospective cohort studies with 
FSH measurement show that ovarian function declines more rapidly and that menopause 
occurs earlier compared with same-age women who have not had hysterectomy.19,40,41 For 
example, premenopausal women who have had hysterectomy with ovarian preservation 
reach menopause (confirmed by FSH levels >40 IU), on average, 3.7 years earlier than 
similar-age women who have not had hysterectomy. Furthermore, among women who have 
had hysterectomy, those who have had unilateral oophorectomy reached menopause 4.4 
years earlier than women with both ovaries preserved.40
CONCLUSIONS
CFS in women is associated with self-reported menstrual abnormalities, endometriosis, 
pelvic pain unrelated to menstruation, early age at hysterectomy/surgical menopause, and 
other gynecologic conditions and surgical operations. It should be emphasized, however, that 
our findings do not demonstrate causality. These findings could be used for further 
hypothesis generation for future studies. Nevertheless, the significantly higher prevalence of 
various gynecologic conditions in women with CFS warrants clinicians’ attention on 
tailoring these women’s medical care. Gynecologists need to be aware that women who have 
had early hysterectomy and/or other gynecologic conditions discussed here may be at risk 
for CFS. Therefore, gynecologists need to assess these women periodically for symptoms 
suggestive of CFS (such as persisting/relapsing problems with memory and concentration, 
sleep problems, muscle and joint pain without swelling or redness, persistent or relapsing 
fatigue that reduces previous levels of functioning, headaches of new onset or severity, 
postexertional malaise [ie, worsening of symptoms after mental or physical exertion], and 
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other symptoms; for a detailed list of symptoms and differential diagnosis, see Fukuda et 
al1). When CFS is suspected, supportive care and appropriate clinical referrals are needed. 
Similarly, physicians seeing women with CFS need to carefully evaluate their gynecologic 
history for risk factors associated with CFS and work with gynecologists for further 
management of identified gynecologic problems. The exact reasons for the reported 
associations cannot be determined from this study; future studies need to examine whether 
any of the associations reported here may be pathophysiologically related to the onset or 
perpetuation of CFS in some women. Further work may be warranted to determine whether 
aberrations in endogenous sex hormones contribute to the pathogenesis and/or perpetuation 
of CFS in a subset of women with this illness.
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FIG. 1. 
Flow chart of the baseline (T0) and follow-up (T1) study of fatiguing illness in Georgia 
showing recruitment of chronic fatigue syndrome (CFS) cases and controls. CATI, 
computer-assisted telephone interview; ISF, insufficient number of symptoms and/or fatigue 
to meet full CFS case definition criteria.
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FIG. 2. 
Schema of possible links between various gynecologic conditions found to be associated 
with chronic fatigue syndrome (in this and other studies). This conceptual model warrants 
further investigation. Boxed text, findings from this study; underlined text and dotted black 
lines, findings/hypothesis from other studies. *Reported by Studd and Panay9; hypothesized 
by Harlow et al,8 by Boneva et al,10 and in the current study. PCOS, polycystic ovary 
syndrome.
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TABLE 1
Demographic characteristics of the CFS and control groups
Variable CFS (n = 84) Control (n = 73) P
Age, mean (SEM), ya 48.3 (1.0) 46.5 (1.2) 0.24
Body mass index, mean (SEM), kg/m2 28.8 (0.6) 25.3 (0.6) 0.0002
Racea 0.26
 Black 14 (16.7) 12 (16.4)
 White 67 (79.8) 61 (83.6)
 Other 3 (3.5) 0 (0)
Geographic stratuma 0.34
 Urban 27 (32.1) 21 (28.8)
 Rural 46 (54.8) 36 (49.3)
 Metropolitan 11 (13.1) 16 (21.9)
Household income 0.10
 Missing data 6 (7.1) 2 (2.7)
 <US$30,000 18 (21.4) 7 (9.6)
 US$30,000-60,000 24 (28.6) 27 (37.0)
 >US$60,000 36 (42.9) 37 (50.7)
Education 0.024
 Less than high school 3 (3.6) 1 (1.4)
 High school 19 (22.6) 9 (12.3)
 ≤3 y of college 32 (38.1) 19 (26.0)
 ≥4 y of college 29 (34.5) 44 (60.3)
 No data 1 (1.2) 0 (0)
Marital status 0.038
 Married 55 (65.5) 49 (67.1)
 Divorced, widowed, or separated 25 (29.8) 12 (16.4)
 Never married 4 (4.8) 11 (15.1)
 No data 0 (0) 1 (1.4)
Data are presented as n (%), unless otherwise specified.
CFS, chronic fatigue syndrome.
aVariable on which controls were matched to CFS-like cases based on detailed telephone interview before clinical evaluation.
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TABLE 3
Risk indicators for CFS in postmenopausal women
Postmenopausal women only CFS (n = 52) Control (n = 27) OR (95% CI) P
Age at menopause onset (all), mean (SEM), y 38.5 (1.3) 48.6 (0.9) NA <0.001
Time since menopause, mean (SEM), y 13.5 (1.3) 7.2 (0.9) NA 0.002
Age at natural menopause, mean (SEM), y 48.6 (1.7) [n = 11] 50.6 (0.5) [n = 17] NA 0.25
Hysterectomy, n (%)a 41 (78.8) 10 (37.0) 6.34 (2.27-17.68) <0.001
Age at hysterectomy, mean (SEM), y 35.8 (1.2) 45.2 (1.8) NA <0.05
Early surgical menopause (aged ≤45 y), n (%) 32/52 (61.5) 9/27 (33.3) 3.20 (1.21-8.49) 0.02
CFS, chronic fatigue syndrome; OR, odds ratio; NA, not applicable.
a
The numbers differ from those in Table 2 because not all women with reported hysterectomy considered themselves postmenopausal.
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TABLE 4
Comparison of the CFS and control groups by reason for gynecologic surgical operation involving removal of 
the uterus and/or ovaries/tubes
Reason for surgical operation involving removal of the uterus and/or 
ovaries/tubes
Among women with surgical operations only
CFS (n = 37) Controls (n = 13) OR (95% CI) P
Endometriosis 7 (18.9) 3 (23.1) 0.78 (0.14-5.57) 0.75a
Uterine fibroids 12 (32.4) 3 (23.1) 1.60 (0.32-10.61) 0.53a
Bleeding 19 (51.4) 2 (15.4) 5.81 (1.01-59.12) 0.02a
Ovarian cysts 11 (29.7) 3 (30.8) 1.41 (0.32-6.14) 0.73a
Abnormal Papanicolaou test findings or precancerous cervical lesions 3 (8.1) 1 (7.7) 1.06 (0.08-60.16) 0.96a
Data are presented as n (%).
CFS, chronic fatigue syndrome; OR, odds ratio.
a
Fisher’s exact test.
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